bluuebunny/crossref_metadata_2025 huggingface dataset:
Calibration-free feedforward temperature compensation for wireless clock synchronisation
Authors: Terraneo Federico , Khalid Zaigham , Fornaciari William , Leva Alberto
Published: February 2025

Wireless systems are entering the
arena
of time-critical applications, including industrial controls. This makes clock synchronisation vital. A relevant source of synchronisation errors, especially in heavy-duty applications and harsh environments, is given by temperature variations that affect the quartz oscillators. This paper takes a control theory-based approach and proposes to augment clock synchronisation schemes – that are typically feedback-based – with a feedforward compensation path using temperature measurements to quickly react to temperature change. Unlike previous approaches relying on per-device data, our solution takes advantage of the combined feedforward-feedback nature of the control scheme to perform compensation using only nominal crystal parameters. When implemented in conjunction with the FLOPSYNC-2 feedback-based clock synchronisation scheme and tested both in simulation and experimentally, the approach resulted in a greatly reduced synchronisation error during temperature transients. In detail, Monte Carlo simulations show that the proposed solution can reduce the peak clock synchronisation error on average by 5.3

\(\times\)

and in the worst case by 2.2

\(\times\)

, thus proving applicable and effective without the need for a costly per-device calibration. When tested experimentally on a network of sensor nodes, a 3.3

\(\times\)

peak clock synchronisation error improvement was observed, confirming the simulation predictions.
Diagnostic Assays Enabled by Engineered Nanoparticles
Authors: Lu Boxi , Cai Yanwei , Wang Dou , Jiang Xingyu
Published: February 2025

Nanoparticles have broad applications in medical diagnosis, bioengineering, and various other domains. Engineered nanoparticles are pivotal in enhancing in vitro detection performance. Utilizing signal readouts such as bioluminescence, fluorescence, and others, nanoparticles enable precise, real-time monitoring of a wide range of analytes. Furthermore, nanoparticles are ingeniously designed to improve the efficiency of in vivo imaging. Nanoparticles are integral to both deep-body imaging, which utilizes advanced techniques such as magnetic resonance imaging or computed tomography (CT), and high-resolution, real-time optical imaging, which are essential for applications such as fluorescence-guided surgery. Here, we highlight these impactful diagnostic assays enabled by engineered nanoparticles, comparing their advantages and disadvantages extensively. For the introduction of each method, we compare the most classic and latest research as much as possible to provide a comprehensive perspective. Finally, we summarize the current limitations and challenges of nanoparticles for diagnostic analysis while also exploring future trends and prospects.
Recent Trends in Surface-Enhanced Raman Scattering–Based In Vitro Diagnostics for Translational Biomedical Research
Authors: Joung Younju , Park Sohyun , Joo Sang Woo , Choo Jaebum
Published: February 2025

Surface-enhanced Raman scattering (SERS) spectroscopy has gained prominence in in vitro diagnostics due to its high sensitivity and multiplex detection capabilities. This review highlights recent advances in translational biomedical research using SERS techniques, with a focus on the rapid and accurate diagnosis of intractable diseases such as cancer and infectious diseases such as COVID-19. The review examines SERS-based assays for liquid biopsy biomarkers such as exosomes, circulating tumor cells, and circulating tumor DNAs that have emerged as promising tools in cancer diagnostics and are currently under active investigation in clinical research. Additionally, it explores SERS-based diagnostic techniques developed to overcome the limitations of existing COVID-19 diagnostic methods, including real-time polymerase chain reaction and lateral flow assay immunodiagnostics. Finally, the review addresses the challenges of translating SERS techniques from laboratory research to clinical practice.
Quantum State–Resolved Structure and Dynamics of C60 Fullerenes
Authors: Liu Lee R. , Ye Jun
Published: February 2025

The C60 fullerene molecule has been the subject of intense study for four decades, starting with its identification in the mass spectra of carbon soot in 1985. In this review, we focus on the achievement of ultra-high-resolution spectroscopy of gas phase neutral C60, heralded by the observation of quantum state–resolved infrared spectra in 2019. C60 is now the largest and most symmetric molecule for which rovibrational quantum state resolution has been achieved, motivating the use of large molecules for studying complex quantum systems with symmetries and degrees of freedom not readily available in other composite systems. We discuss the theory, challenges, and experimental techniques of high-resolution C60 spectroscopy and recent experimental results probing the structure, dynamics, and interactions of C60 enabled by quantum state resolution.
Citric Acid as a Small Molecule Binder for Si-Based Li-Ion Battery Anode Materials
Authors: Salehabadi Mina , Medhi K. , Werner-Zwanziger U. , Obrovac M. N.
Published: February 2025

In this study, citric acid (CA) dissolved in propylene glycol (PG) was shown to be an effective binder/solvent system for Si-based anode materials in Li-ion batteries. In this system, PG serves both as a slurry solvent and provides viscosity to the slurry to inhibit the settling of active particles and for proper rheology during the coating process, while the small CA molecule serves as a binder/artificial solid electrolyte interphase. After 50 cycles, SiO/carbon black/CA electrodes had a higher capacity retention (93%) than conventional electrodes with lithium polyacrylate (LiPAA) polymeric binder (68%), due to superior maintenance of adhesion amongst active particles. This demonstrates that small molecules may be used as effective binders for Si-based anode materials when a slurry solvent is used that can take on the role of maintaining the slurry rheology.
Study on the Performance of GaN Homoepitaxial Films Grown on Polished Substrates by Different Slurries
Authors: Zhou Yan , Gong Hua , Luo Haimei , Chen Gaopan , Luo Guihai , Pan Liyan , Pan Guoshun
Published: February 2025

GaN is considered one of the most promising wide-band-gap semiconductor materials, which has attracted significant attention due to its excellent properties. Here, the performance of the GaN homoepitaxial films grown on different polished substrates by Al2O3 slurry and SiO2 slurry respectively are studied. Atomic force microscope observation shows that the GaN homoepitaxial film grown on polished GaN substrate by the SiO2 slurry could exhibit low-roughness ultra-smooth surface and step-flow growth mode morphology, compared to that grown on the polished GaN substrate by Al2O3 slurry. High-resolution X-ray diffraction, Raman, photoluminescence, and cathodoluminescence measurements are used to investigate the characteristics of the homoepitaxial GaN films on the polished GaN substrates by different slurries. The results indicate that GaN homoepitaxial film grown on the ultra-smooth GaN substrate polished by SiO2 slurry has better crystalline quality, less impurities/defects, lower residual stress, and near stress-free, which has great potential for more advanced devices.
X-ray Computed Microtomography Evaluation of Electrochemically Accelerated Stainless Steel Crevice Corrosion
Authors: Hangarter Carlos M. , Geltmacher Andrew B. , Tailleart Nicole R. , Callahan Patrick G. , Watring Dillon S. , Olig Scott M. , Kinee William
Published: February 2025

This work reports the electrochemical and X-ray tomography characterization of crevice corrosion for an additively manufactured stainless steel. The cell design includes a three electrode configuration with an integrated crevice former for full electrochemical control. The crevice former design utilized a spring to induce force upon the crevice former and tape to defined the crevice. The cell was evaluated with a series of potentiostatic holds from 0.05 to 0.95 VSCE to observe crevice corrosion initiation and propagation across a range of current densities. In this proof of concept demonstration, X-ray computed microtomography (XCMT) reconstructions were used to observe electrochemical potential dependent crevice corrosion propagation that was compared with coulometry and postmortem profilometry. Volume loss calculations based on XCMT reconstructions displayed good correlation with electrochemical measurements. We demonstrate this approach as a promising non-destructive tool for crevice corrosion characterization, limited primarily by the inherent limitations of X-ray tomography systems.
Table S2 from Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers
Authors: Chen Yun-Ching , Hsu Chia-Lang , Wang Hui-Min , Wu Shang-Gin , Chang Yih-Leong , Chen Jin-Shing , Wu Yu-Ching , Lin Yen-Ting , Yang Ching-Yao , Lin Mong-Wei , Lee Jang-Ming , Kuo Shuenn-Wen , Chen Ke-Cheng , Hsu Hsao-Hsun , Huang Pei-Ming , Huang Yen-Lin , Yu Chong-Jen , Pirooznia Mehdi , Huang Bevan E. , Yang Rob , Shih Jin-Yuan , Yang Pan-Chyr
Published: February 2025

Table S2. scRNA cell-type markers.
Table S1 from Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers
Authors: Chen Yun-Ching , Hsu Chia-Lang , Wang Hui-Min , Wu Shang-Gin , Chang Yih-Leong , Chen Jin-Shing , Wu Yu-Ching , Lin Yen-Ting , Yang Ching-Yao , Lin Mong-Wei , Lee Jang-Ming , Kuo Shuenn-Wen , Chen Ke-Cheng , Hsu Hsao-Hsun , Huang Pei-Ming , Huang Yen-Lin , Yu Chong-Jen , Pirooznia Mehdi , Huang Bevan E. , Yang Rob , Shih Jin-Yuan , Yang Pan-Chyr
Published: February 2025

Table S1. Cell-type annotations for the scRNA data
Supplementary Data from Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers
Authors: Chen Yun-Ching , Hsu Chia-Lang , Wang Hui-Min , Wu Shang-Gin , Chang Yih-Leong , Chen Jin-Shing , Wu Yu-Ching , Lin Yen-Ting , Yang Ching-Yao , Lin Mong-Wei , Lee Jang-Ming , Kuo Shuenn-Wen , Chen Ke-Cheng , Hsu Hsao-Hsun , Huang Pei-Ming , Huang Yen-Lin , Yu Chong-Jen , Pirooznia Mehdi , Huang Bevan E. , Yang Rob , Shih Jin-Yuan , Yang Pan-Chyr
Published: February 2025

Supplementary Information
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Authors: Lamoureux Audrey-Anne , Fisher Michael J. , Lemelle Lauriane , Pfaff Elke , Amir-Yazdani Pouneh , Kramm Christof , De Wilde Bram , Kazanowska Bernarda , Hutter Caroline , Pfister Stefan M. , Sturm Dominik , Jones David T.W. , Orbach Daniel , Pierron Gaëlle , Raskin Scott , Drilon Alexander , Diamond Eli L. , Harada Guilherme , Zapotocky Michal , Zamecnik Josef , Krskova Lenka , Ellezam Benjamin , Weil Alexander G. , Venne Dominic , Barritault Marc , Leblond Pierre , Coltin Hallie , Hammad Rawan , Tabori Uri , Hawkins Cynthia , Hansford Jordan R. , Meyran Deborah , Erker Craig , McFadden Kathryn , Sato Mariko , Gottardo Nicholas G. , Dholaria Hetal , Nørøxe Dorte Schou , Goto Hiroaki , Ziegler David S. , Lin Frank Y. , Parsons Donald Williams , Lindsay Holly , Wong Tai-Tong , Liu Yen-Lin , Wu Kuo-Sheng , Franson Andrea T. , Hwang Eugene , Aguilar-Bonilla Ana , Cheng Sylvia , Cacciotti Chantel , Massimino Maura , Schiavello Elisabetta , Wood Paul , Hoffman Lindsey M. , Cappellano Andréa , Lassaletta Alvaro , Van Damme An , Llort Anna , Gerber Nicolas U. , Spalato Ceruso Mariella , Bendel Anne E. , Skrypek Maggie , Hamideh Dima , Mushtaq Naureen , Walter Andrew , Jabado Nada , Alsahlawi Aysha , Farmer Jean-Pierre , Coleman Christina , Mueller Sabine , Mazewski Claire , Aguilera Dolly , Robison Nathan J. , O’Halloran Katrina , Abbou Samuel , Berlanga Pablo , Geoerger Birgit , Øra Ingrid , Moertel Christopher L. , Razis Evangelia D. , Vernadou Anastasia , Ducray François , Bronnimann Charlotte , Seizeur Romuald , Clarke Matthew , Resnick Adam C. , Alves Mélanie , Jones Chris , Doz François , Laetsch Theodore W. , Perreault Sébastien
Published: February 2025

Supplementary Table S1. NTRK fusion type and histology.
Supplementary Data 1 from Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies
Authors: Jaeger-Ruckstuhl Carla A. , Specht Jennifer M. , Voutsinas Jenna M. , MacMillan Hugh R. , Wu Qian (Vicky) , Muhunthan Vishaka , Berger Carolina , Pullarkat Shalini , Wright Jocelyn H. , Yeung Cecilia C.S. , Hyun Teresa S. , Seaton Brandon , Aicher Lauri D. , Song Xiaoling , Pierce Robert H. , Lo Yun , Cole Gabriel O. , Lee Sylvia M. , Newell Evan W. , Maloney David G. , Riddell Stanley R.
Published: February 2025

Supplementary Data 1: Study Protocol.
Supplementary Table S5 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Authors: Cabibbo Giuseppe , Celsa Ciro , Battaglia Salvatore , Enea Marco , Di Maria Gabriele , Grova Alessandro , Ciccia Roberta , Manfredi Giulia F. , Iavarone Massimo , Vogel Arndt , Singal Amit G. , Reig Maria , Pinato David J. , Cammà Calogero
Published: February 2025

Supplementary Table S5. Full multivariable model of baseline predictors of clinical hepatic decompensation and HCC progression by competing risks analysis, with albumin-bilirubin (ALBI) included as continuous variable.
Supplementary Table 4 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Authors: Cabibbo Giuseppe , Celsa Ciro , Battaglia Salvatore , Enea Marco , Di Maria Gabriele , Grova Alessandro , Ciccia Roberta , Manfredi Giulia F. , Iavarone Massimo , Vogel Arndt , Singal Amit G. , Reig Maria , Pinato David J. , Cammà Calogero
Published: February 2025

Supplementary Table 4. Full multivariable model of baseline predictors of clinical hepatic decompensation and HCC progression by competing risks analysis.
Supplementary Table 2 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Authors: Cabibbo Giuseppe , Celsa Ciro , Battaglia Salvatore , Enea Marco , Di Maria Gabriele , Grova Alessandro , Ciccia Roberta , Manfredi Giulia F. , Iavarone Massimo , Vogel Arndt , Singal Amit G. , Reig Maria , Pinato David J. , Cammà Calogero
Published: February 2025

Supplementary Table 2. Patient characteristics at baseline.
Supplementary Table S4 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
Authors: Ferrario Cristiano , Mackey John , Gelmon Karen A. , Levasseur Nathalie , Sorensen Poul H. , Oo Htoo Zarni , Negri Gian L. , Tse Veronica W.L. , Spencer Sandra E. , Cheng Grace , Morin Gregg B. , del Rincon Sonia , Cotechini Tiziana , Gonçalves Christophe , Hindmarch Charles C.T. , Miller Wilson H. , Amiri Mehdi , Basiri Tayebeh , Villareal-Corpuz Victor , Sperry Sam , Gregorczyk Kevin , Spera Gonzalo , Sonenberg Nahum , Pollak Michael
Published: February 2025

Supplementary Table S4. (A) Investigator categorization of adverse events. (B) Overview of adverse events by CTCAE toxicity level.
Supplementary Fig. S1 from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
Authors: Ferrario Cristiano , Mackey John , Gelmon Karen A. , Levasseur Nathalie , Sorensen Poul H. , Oo Htoo Zarni , Negri Gian L. , Tse Veronica W.L. , Spencer Sandra E. , Cheng Grace , Morin Gregg B. , del Rincon Sonia , Cotechini Tiziana , Gonçalves Christophe , Hindmarch Charles C.T. , Miller Wilson H. , Amiri Mehdi , Basiri Tayebeh , Villareal-Corpuz Victor , Sperry Sam , Gregorczyk Kevin , Spera Gonzalo , Sonenberg Nahum , Pollak Michael
Published: February 2025

Supplementary Fig. S1: Pharmacokinetic data. Circulating tomivosertib concentrations in healthy volunteers showing similarity of administering 100 mg tomivosertib with food or 200 mg tomivosertib without food (data from by eFFECTOR Therapeutics).
Supplementary Figure S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Authors: Mastrolonardo Eric V. , Nunes Kathryn L. , Llerena Pablo , Nikitina Anastasia , Sobol Anastasia , Scott E. Reilly , Tuluc Madalina , Davitt Christopher J.H. , Scher Jessica , Tekumalla Sruti , Mann Derek , Henao Camilo , Jegede Victor , Gargano Stacey , Harshyne Larry A. , Alnemri Angela , Tyshevich Andrey , Kushnarev Vladimir , Chasse Madison , Sookiasian Danielle , Axelrod Rita , Zhan Tingting , Leiby Benjamin E. , Old Matthew , Seim Nolan , Mahoney My G. , Martinez-Outschoorn Ubaldo , Cognetti David M. , Curry Joseph M. , Prendergast George , Argiris Athanassios , South Andrew P. , Linnenbach Alban J. , Johnson Jennifer M. , Luginbuhl Adam J.
Published: February 2025

Supplement Figure 4: STRING Networks enlarged. The STRING networks of B cell (A) and CAF (B) as visualized in Figure 5.
Supplementary Figure S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Authors: Mastrolonardo Eric V. , Nunes Kathryn L. , Llerena Pablo , Nikitina Anastasia , Sobol Anastasia , Scott E. Reilly , Tuluc Madalina , Davitt Christopher J.H. , Scher Jessica , Tekumalla Sruti , Mann Derek , Henao Camilo , Jegede Victor , Gargano Stacey , Harshyne Larry A. , Alnemri Angela , Tyshevich Andrey , Kushnarev Vladimir , Chasse Madison , Sookiasian Danielle , Axelrod Rita , Zhan Tingting , Leiby Benjamin E. , Old Matthew , Seim Nolan , Mahoney My G. , Martinez-Outschoorn Ubaldo , Cognetti David M. , Curry Joseph M. , Prendergast George , Argiris Athanassios , South Andrew P. , Linnenbach Alban J. , Johnson Jennifer M. , Luginbuhl Adam J.
Published: February 2025

Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.
Supplementary Appendix S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Authors: Mastrolonardo Eric V. , Nunes Kathryn L. , Llerena Pablo , Nikitina Anastasia , Sobol Anastasia , Scott E. Reilly , Tuluc Madalina , Davitt Christopher J.H. , Scher Jessica , Tekumalla Sruti , Mann Derek , Henao Camilo , Jegede Victor , Gargano Stacey , Harshyne Larry A. , Alnemri Angela , Tyshevich Andrey , Kushnarev Vladimir , Chasse Madison , Sookiasian Danielle , Axelrod Rita , Zhan Tingting , Leiby Benjamin E. , Old Matthew , Seim Nolan , Mahoney My G. , Martinez-Outschoorn Ubaldo , Cognetti David M. , Curry Joseph M. , Prendergast George , Argiris Athanassios , South Andrew P. , Linnenbach Alban J. , Johnson Jennifer M. , Luginbuhl Adam J.
Published: February 2025

Supplementary Appendix
Table 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Altan Mehmet , Lopes Gilberto , Hiltermann T. Jeroen N. , Govindan Ramaswamy , Villaruz Liza C. , Calvo Emiliano , Edelman Martin J. , Furqan Muhammad , Neal Joel , Felip Enriqueta , Carlisle Jennifer W. , Heymach John V. , O’Cearbhaill Róisín Eilish , Zauderer Marjorie , Chisamore Michael , Corigliano Ellie , Eleftheriadou Ioanna , Zajic Stefan , Jenkins Ben , Goodison Sophia , Suchindran Sunil , Ramos-Hernandez Natalia , Tarek Nidale , Schoenfeld Adam J.
Published: February 2025

Patient characteristics: tumor stage and histology, prior therapy, LDR, and lete-cel treatment (mITT population).
Supplementary Table S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Table S4. Additional patient characteristics of HPV positive HNSCC patients.
Supplementary Table S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Table S1. Multiparametric 15-color flow cytometry panel used for analysis of human PBMCs, including Treg (CD4+Foxp3+), and functional markers for T cells (GrnzB, IFNγ, and PD-1).
Supplementary Figure 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Altan Mehmet , Lopes Gilberto , Hiltermann T. Jeroen N. , Govindan Ramaswamy , Villaruz Liza C. , Calvo Emiliano , Edelman Martin J. , Furqan Muhammad , Neal Joel , Felip Enriqueta , Carlisle Jennifer W. , Heymach John V. , O’Cearbhaill Róisín Eilish , Zauderer Marjorie , Chisamore Michael , Corigliano Ellie , Eleftheriadou Ioanna , Zajic Stefan , Jenkins Ben , Goodison Sophia , Suchindran Sunil , Ramos-Hernandez Natalia , Tarek Nidale , Schoenfeld Adam J.
Published: February 2025

Supplementary Figure 1. Patient journey
Supplementary Figure S4 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Figure S4. Gating strategy for flow cytometry analysis of PBMC.
Supplementary Figure S1 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Figure S1. Survival curves for phase 1 study patients based on Kaplan-Meier analysis.
Supplementary Table S2 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Authors: White Michael G. , Zeineddine Mohammad A. , Fallon Eleanor A. , Zeineddine Fadl A. , Dansby Julia , Chowdhury Saikat , Hornstein Nicholas , Yousef Abdelrahman , Yousef Mahmoud , Bhutiani Neal , Gu Yue , Kee Bryan , Dasari Arvind , Overman Michael J. , Raghav Kanwal , Kopetz Scott , Uppal Abhineet , Taggart Melissa , Newhook Timothy , Fournier Keith , Helmink Beth , Drusbosky Leylah M. , Shen John Paul
Published: February 2025

Supplementary Table S2: Co-occuring circulating mutations in AA
Supplementary Table S2 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Authors: Mamidi Murali K. , Sinha Sutapa , Mendez Mariana T. , Sanyal Tapojyoti , Mahmud Hasan , Kay Neil E. , Gupta Mamta , Xu Chao , Vesely Sara K. , Mukherjee Priyabrata , Holter Chakrabarty Jennifer , Ghosh Asish K.
Published: February 2025

Supplementary Table S2. Primer sets used in the study.
Supplementary Figure S10 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Authors: Mamidi Murali K. , Sinha Sutapa , Mendez Mariana T. , Sanyal Tapojyoti , Mahmud Hasan , Kay Neil E. , Gupta Mamta , Xu Chao , Vesely Sara K. , Mukherjee Priyabrata , Holter Chakrabarty Jennifer , Ghosh Asish K.
Published: February 2025

Supplementary Figure S10. Summary diagram.
Data from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Authors: Cabibbo Giuseppe , Celsa Ciro , Battaglia Salvatore , Enea Marco , Di Maria Gabriele , Grova Alessandro , Ciccia Roberta , Manfredi Giulia F. , Iavarone Massimo , Vogel Arndt , Singal Amit G. , Reig Maria , Pinato David J. , Cammà Calogero
Published: February 2025

AbstractPurpose:
The prognosis of patients with unresectable hepatocellular carcinoma (HCC) and compensated cirrhosis is influenced by cancer progression. Data on the incidence and the prognostic role of clinical hepatic decompensation (CHD) following immune checkpoint inhibitor therapy are lacking. We aimed to assess whether early CHD within 3 months from commencement of systemic therapy affects overall survival (OS) of patients treated with atezolizumab plus bevacizumab or sorafenib.
Patients and Methods:
Individual patient data from the IMbrave150 trial were analyzed. Cumulative incidence of CHD was assessed by competing risk analysis against HCC radiologic progression. Early CHD and HCC radiologic progression were assessed as predictors of OS by the time-dependent Cox model.
Results:
The 3- and 12-month rates of CHD were 7% and 12%, respectively, whereas the 3- and 12-month rates of HCC radiologic progression were 23% and 52%, respectively. Albumin–bilirubin grade 2 [subdistribution HR (sHR) = 1.79, 95% confidence interval (CI), 1.01–3.19; P = 0.049], INR (sHR = 1.97, 95% CI, 1.64–2.37; P < 0.001), and presence of neoplastic macrovascular invasion (sHR = 2.01, 95% CI, 1.14–3.54; P = 0.020) were independently associated with higher risk of CHD. Early CHD (HR = 7.56, 95% CI, 4.47–12.8) and early HCC radiologic progression (HR = 5.92, 95% CI, 4.03–8.69), as first events, were independently associated with higher mortality.
Conclusions:
This study provides robust evidence that early CHD is associated with the highest risk of death in patients with unresectable HCC undergoing systemic treatment. Within well-compensated participants, albumin–bilirubin, INR, and macrovascular invasion identify a population at higher risk of decompensation. Inclusion of clinical decompensation events in future prospective clinical trials may improve characterization of OS from systemic therapy of HCC.
Supplementary Table S5 from Characteristics of a CCL21 Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer
Authors: Oh Michael S. , Dumitras Camelia , Salehi-Rad Ramin , Tran Linh M. , Krysan Kostyantyn , Lim Raymond J. , Jing Zhe , Tappuni Shahed , Lisberg Aaron , Garon Edward B. , Dubinett Steven M. , Liu Bin
Published: February 2025

Supplementary Table S5. Differentially expressed genes in CCL21-DC vaccines from healthy donors vs patients.
Figure S2 from OBI-992, a Novel TROP2-Targeted Antibody–Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
Authors: Li Wan-Fen , Chiang Ming-Feng , Weng Hao-Cheng , Yang Jhih-Jie , Wu Hsin-Shan , Wu Szu-Yu , Chen Yu-Jung , Lu Chi‐Huan , Tu Jyy-Shiuan , Hsu Ren-Yu , Shia Chi-Sheng , Huang Teng-Yi , Lai Ming-Tain
Published: February 2025

Supplementary Figure S2
Figure S1 from HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with Irradiation
Authors: Hayrapetyan Liana , Roth Selina M. , Quintin Aurélie , Hovhannisyan Lusine , Medo Matúš , Riedo Rahel , Ott Julien G. , Albers Joachim , Aebersold Daniel M. , Zimmer Yitzhak , Medová Michaela
Published: February 2025

Cell proliferation (crystal violet assays): (A) Representative images of crystal violet assay. (B) Response (1.0 - cell proliferation) as a function of the IR dose for treated (Peposertib) and untreated (Control) cell lines. Data is represented as a mean of three replicates±SEM. Green lines show the median fit of the Emax model to the input data (see Materials and Methods). The Dose Modifying Factor (DMF) values are the ratios between the IR doses needed to reach response 0.5 (LD50) in untreated and treated cells, respectively.
Table S2 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
Authors: Kantak Seema , Faggioni Raffaella , Cai Allen G. , Bhatti Maryam M. , Li Jing , Vainshtein Inna , Cheng Jackie , Mendelsohn Brian A. , Gaudreault Jacques , Migone Thi-Sau , Theunissen Jan-Willem
Published: February 2025

Pharmacokinetic profile of anti-TF mAb 25A3 with zovodotin linker-payload (XB002) or vedotin linker-payload
Table S2 from Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody–Drug Conjugate for Enhanced Antitumor Efficacy in Solid Tumors
Authors: Wang Zeng , Zheng Meijun , Li Mengyao , Lu Huaqing , Liu Nanxi , Chen Yongdong , Yang Nian , Zeng Wanqin , Dong Yijun , Li Jia , Zhu Zhixiong , Yang Chen , Zhang Zongliang , Lu Qizhong , Li Hexian , Zhou Liangxue , Yang Hui , Tong Aiping
Published: February 2025

Supplementary Table 2. The sequence of 19G4 antibody.
Figure S7 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
Authors: Kantak Seema , Faggioni Raffaella , Cai Allen G. , Bhatti Maryam M. , Li Jing , Vainshtein Inna , Cheng Jackie , Mendelsohn Brian A. , Gaudreault Jacques , Migone Thi-Sau , Theunissen Jan-Willem
Published: February 2025

Effect of XB002 on neutrophil levels
Figure S6 from Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors
Authors: Kantak Seema , Faggioni Raffaella , Cai Allen G. , Bhatti Maryam M. , Li Jing , Vainshtein Inna , Cheng Jackie , Mendelsohn Brian A. , Gaudreault Jacques , Migone Thi-Sau , Theunissen Jan-Willem
Published: February 2025

Internalization of fluorescently tagged XB002
Supplementary Data S1 from Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the ATM Inhibitor WSD0628
Authors: Garcia Darwin A. , Rathi Sneha , Connors Margaret A. , Grams Michael , Vaubel Rachael A. , Bakken Katrina K. , Ott Lauren L. , Carlson Brett L. , Hu Zeng , Decker Paul A. , Eckel-Passow Jeanette E. , Burgenske Danielle M. , Zhong Wei , Trzasko Joshua D. , Herman Michael G. , Elmquist William F. , Remmes Nicholas B. , Sarkaria Jann N.
Published: February 2025

Supplementary Data S1: the positioning reproducibility was determined for esophagus irradiations.
Supplementary Figure S4 from Alcohol Consumption Does not Modify the Polygenic Risk Score–Based Genetic Risk of Breast Cancer in Postmenopausal Women: Atherosclerosis Risk in Communities Study
Authors: Zhang Minghui , Ru Meng , Zhang Jingning , Wang Ziqiao , Lu Jiayun , Butler Kenneth R. , Chatterjee Nilanjan , Couper David J. , Prizment Anna E. , Soori Mehrnoosh M. , Visvanathan Kala , Zahnow Cynthia A. , Joshu Corinne E. , Platz Elizabeth A.
Published: February 2025

Supplementary Figure S4: Natural logarithm hazard ratios of breast cancer for P-spline term current ethanol intake with 4 degrees of freedom estimated by fully-adjusted Cox proportional hazards model in ARIC (1990-2015)
Supplemental Table 7 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Authors: Karra Prasoona , Hardikar Sheetal , Winn Maci , Anderson Garnet L. , Haaland Benjamin , Shadyab Aladdin H. , Neuhouser Marian L. , Seguin-Fowler Rebecca A. , Thomson Cynthia A. , Coday Mace , Wactawski-Wende Jean , Stefanick Marcia L. , Zhang Xiaochen , Cheng Ting-Yuan David , Karanth Shama , Sun Yangbo , Saquib Nazmus , Pichardo Margaret S. , Jung Su Yon , Tabung Fred K. , Summers Scott A. , Holland William L. , Jalili Thunder , Gunter Marc J. , Playdon Mary C.
Published: February 2025

Supplemental Table 7. Association between metabolic phenotypes defined by Wildman criteria with obesity-related cancer (ORC) risk after excluding participants diagnosed with ORC within the first three years of follow-up in the Women’s Health Initiative cohort (N= 20,320).
Supplemental Figure 1 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Authors: Karra Prasoona , Hardikar Sheetal , Winn Maci , Anderson Garnet L. , Haaland Benjamin , Shadyab Aladdin H. , Neuhouser Marian L. , Seguin-Fowler Rebecca A. , Thomson Cynthia A. , Coday Mace , Wactawski-Wende Jean , Stefanick Marcia L. , Zhang Xiaochen , Cheng Ting-Yuan David , Karanth Shama , Sun Yangbo , Saquib Nazmus , Pichardo Margaret S. , Jung Su Yon , Tabung Fred K. , Summers Scott A. , Holland William L. , Jalili Thunder , Gunter Marc J. , Playdon Mary C.
Published: February 2025

Supplemental Figure 1. Study Schematic of Women’s Health Initiative Participant Selection. Flowchart detailing the selection process of study participants, and the final cohort size for the study.
Data from Alcohol Consumption Does not Modify the Polygenic Risk Score–Based Genetic Risk of Breast Cancer in Postmenopausal Women: Atherosclerosis Risk in Communities Study
Authors: Zhang Minghui , Ru Meng , Zhang Jingning , Wang Ziqiao , Lu Jiayun , Butler Kenneth R. , Chatterjee Nilanjan , Couper David J. , Prizment Anna E. , Soori Mehrnoosh M. , Visvanathan Kala , Zahnow Cynthia A. , Joshu Corinne E. , Platz Elizabeth A.
Published: February 2025

Abstract
High genetic risk and alcohol consumption ≥1 drink/day are associated with increased breast cancer risk. However, the interaction between alcohol and genetics on breast cancer risk is poorly understood, including in populations not enriched with daily drinkers. We prospectively studied 5,651 White and Black postmenopausal women in the Atherosclerosis Risk in Communities study. Alcohol intake was assessed by a food frequency questionnaire. The 313-SNP polygenic risk score (PRS) was calculated. Breast cancer cases were ascertained primarily by cancer registry linkage through 2015. Multivariable Cox regression was used to estimate HRs and 95% confidence intervals (CI) for the association of PRS and current ethanol intake with breast cancer, and their interaction. Of these individuals, 50.6% were current drinkers, and of them, 50.8% drank <1 drink/week and 12.8% drank >7 drinks/week. A higher PRS was associated with a higher breast cancer risk among White (HR1-SD, 1.48; 95% CI, 1.34–1.65) and Black (HR1-SD, 1.15; 95% CI, 0.96–1.38) women. Positive associations were not observed between current ethanol intake and breast cancer risk (White: HR13 g/week, 1.00; 95% CI, 0.98–1.03; Black: HR, 0.83; 95% CI, 0.69–1.00). Among both White and Black women, PRS generally seemed to be positively associated with risk in drinkers and nondrinkers. There was no evidence of a PRS–ethanol intake interaction among White or Black women. Patterns in Black women were similar when using an 89-SNP PRS developed among African ancestry women. In conclusion, in a prospective analysis of White and Black postmenopausal women in a study population not enriched with daily drinkers, our findings suggest that alcohol drinking does not modify the PRS-based genetic risk of breast cancer.

Prevention Relevance: Although our findings suggest that alcohol drinking does not modify the PRS-based genetic risk of breast cancer among White and Black women with lower alcohol intake, nevertheless, women should consider limiting alcohol consumption as a general cancer prevention strategy, as indicated in dietary guidelines.
Figure S6 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Authors: Phung Shee Kwan , Zorko Nicholas A. , Soignier Yvette , Waller Rhett L. , Shackelford Madison , Walker Joshua T. , Nelson Trygve D. , Selleck Carly , Bendzick Laura E. , Kotz Laura E. , Kile Quinlan M. , Bozicevich Asha J. , Miller Sarah E. , Khaw Melissa , Shetty Mihir , Hinderlie Peter , Ehrhardt Michael , Li Yingming , Luo Xianghua , Dehm Scott M. , Antonarakis Emmanuel S. , Kennedy Philippa R. , Miller Jeffrey S. , Felices Martin
Published: February 2025

MDSC phenotype and suppression.
Figure S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Authors: McGeary Meaghan K. , Damsky William , Daniels Andrew J. , Lang Sabine M. , Xu Qingji , Song Eric , Huet-Calderwood Clotilde , Lou Hua Jane , Paradkar Sateja , Micevic Goran , Kaech Susan M. , Calderwood David A. , Turk Benjamin E. , Yan Qin , Iwasaki Akiko , Bosenberg Marcus W.
Published: February 2025

Figure S4: Evaluation of differences in SKO tumor gene expression and microenvironment profiles, related to Figure 3:
Figure S9 from Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
Authors: Morita Satoru , Lei Pin-Ji , Shigeta Kohei , Ando Tomofumi , Kobayashi Tatsuya , Kikuchi Hiroto , Matsui Aya , Huang Peigen , Pittet Mikael J. , Duda Dan G.
Published: February 2025

Supplementary Figure S9
Figure S7 from Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
Authors: Morita Satoru , Lei Pin-Ji , Shigeta Kohei , Ando Tomofumi , Kobayashi Tatsuya , Kikuchi Hiroto , Matsui Aya , Huang Peigen , Pittet Mikael J. , Duda Dan G.
Published: February 2025

Supplementary Figure S7
Figure S2 from Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
Authors: Morita Satoru , Lei Pin-Ji , Shigeta Kohei , Ando Tomofumi , Kobayashi Tatsuya , Kikuchi Hiroto , Matsui Aya , Huang Peigen , Pittet Mikael J. , Duda Dan G.
Published: February 2025

Supplementary FIgure S2
Figure S9 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Authors: Sun Yi , Maggs Luke , Panda Apekshya , Wright Samuel J. , Cicerchia Angelina M. , Jenney Anne , Perricone Matthew D. , Mills Caitlin E. , Cattaneo Giulia , Ventin Marco , Chen Feng , Rasmussen Martin Q. , Miranda Alex , Revach Or-Yam , Fang Jacy , Fu Amina , Bowling Peter J. , Sharova Tatyana , Lawless Aleigha , Sorger Peter K. , Bardeesy Nabeel , Wang Xinhui , Flaherty Keith T. , Boland Genevieve M. , Mehta Arnav , Sade-Feldman Moshe , Ferrone Cristina R. , Jenkins Russell W.
Published: February 2025

Supplemental Figure S9 | Supporting data for single cell RNA sequencing of CAR-T in 3D co-cultures with PDOTS.
Fig. S2 from Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer
Authors: Fusagawa Minami , Tokita Serina , Murata Kenji , Mariya Tasuku , Umemoto Mina , Sugita Shintaro , Matsuo Kazuhiko , Hirohashi Yoshihiko , Saito Tsuyoshi , Kanaseki Takayuki , Torigoe Toshihiko
Published: February 2025

Fig. S2 | Sequences of the identified neoantigens.
Figure S2 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Authors: Tsuge Ayaka , Watanabe Sho , Kawazoe Akihito , Togashi Yosuke , Itahashi Kota , Masuda Mari , Sai Atsuo , Takei Shogo , Muraoka Hiromi , Ohkubo Shuichi , Sugiyama Daisuke , Yan Yue , Fukuoka Shota , Doi Toshihiko , Shitara Kohei , Koyama Shohei , Nishikawa Hiroyoshi
Published: February 2025

Antigen-specific CD8+ T cells are significantly increased after pimitespib treatment. (A–C). Antigen-specific CD8+ T-cell induction in the presence or absence of pimitespib. Representative flow cytometry staining of antigen-specific CD8+ T cells (left) and summaries of the frequency of antigen-specific CD8+ T cells (right). For in vitro sensitization of antigen-specific CD8+ T cells, 1.5–2.0 × 106 cells were cultured with antigen-presenting cells pulsed with various peptides (Melan-A/MART-1, A; influenza, B; CMV, C) with or without pimitespib (1 μM). Seven to ten days later, pre-sensitized CD8+ T cells were stained with PE-labeled peptide antigen/HLA-A*0201 dextramers and analyzed with flow cytometry. The data shown are representative of three independent experiments. *, P < 0.05; **, P < 0.01.
Supplementary Table S5 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Table S5
Supplementary Figure S3 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Figure S3
Supplementary Figure S1 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Figure S1
Supplementary Tables 1-3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Authors: Tintelnot Joseph , Paschold Lisa , Goekkurt Eray , Schultheiss Christoph , Matschl Urte , Santos Cruz Mariana , Bauer Marcus , Wickenhauser Claudia , Thuss-Patience Peter , Lorenzen Sylvie , Ettrich Thomas J. , Riera-Knorrenschild Jorge , Jacobasch Lutz , Kretzschmar Albrecht , Kubicka Stefan , Al-Batran Salah-Eddin , Reinacher-Schick Anke , Pink Daniel , Bokemeyer Carsten , Sinn Marianne , Lindig Udo , Hinke Axel , Hegewisch-Becker Susanna , Stein Alexander , Binder Mascha
Published: February 2025

Supplementary Tables 1-3
Supplementary Figure S5 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Authors: Hao Yameng , Gkasti Aspasia , Managh Amy J. , Dagher Julien , Sifis Alexandros , Tiron Luca , Chriqui Louis-Emmanuel , Marie Damien N. , De Souza Silva Olga , Christodoulou Michel , Peters Solange , Joyce Johanna A. , Krueger Thorsten , Gonzalez Michel , Abdelnour-Berchtold Etienne , Sempoux Christine , Clerc Daniel , Teixeira-Farinha Hugo , Hübner Martin , Meylan Etienne , Dyson Paul J. , Cavin Sabrina , Perentes Jean Y.
Published: February 2025

Supplementary Figure S5: Impact of HITOC on tumor-infiltrating T cells.
Supplementary Figure S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Authors: Hao Yameng , Gkasti Aspasia , Managh Amy J. , Dagher Julien , Sifis Alexandros , Tiron Luca , Chriqui Louis-Emmanuel , Marie Damien N. , De Souza Silva Olga , Christodoulou Michel , Peters Solange , Joyce Johanna A. , Krueger Thorsten , Gonzalez Michel , Abdelnour-Berchtold Etienne , Sempoux Christine , Clerc Daniel , Teixeira-Farinha Hugo , Hübner Martin , Meylan Etienne , Dyson Paul J. , Cavin Sabrina , Perentes Jean Y.
Published: February 2025

Supplementary Figure S2: Flow cytometry gating.
Figure 4 from Ternary Complex Components Responsible for Rapid LDL Internalization as Biomarkers for Breast Cancer Associated with Proliferation and Early Recurrence
Authors: McDonald Elizabeth S. , Pan Tien-Chi , Pant Dhruv K. , Troester Melissa A. , Kossenkov Andrew V. , Mankoff David A. , Mach Robert H. , Chodosh Lewis A.
Published: February 2025

PAM50, derived Oncotype DX, and a new proliferation score (Prolif224) were all similarly related to RFS. JRH, John Radcliffe Hospital; RFS, recurrence-free survival.
Validation of a Demography-Based Adaptive QT Correction Formula Using Pediatric and Adult Datasets Acquired From Humans and Guinea Pigs
Authors: Haq Kazi T. , McLean Kate M. , Anderson-Barker Grace C. , Berul Charles I. , Shattock Michael J. , Posnack Nikki Gillum
Published: February 2025

BACKGROUND:

QT correction (QTc) formulae are widely used in clinical and research settings but often underperform, possibly due to demographic influences on the QT–heart rate (HR) relationship. To address this limitation, we developed an adaptive QTc (QTcAd) formula, which adjusts for demographic factors like age, and compared its efficacy to other standard formulae.

METHODS:

The QTcAd formula was tested across diverse age groups with different HR in both humans and guinea pigs. Using retrospective ECG data from 1819 pediatric patients at Children’s National Hospital and 2400 subjects from the Pediatric Heart Network database, alongside in vivo (N=55) and ex vivo (N=66) guinea pig ECG recordings, we evaluated the formula’s effectiveness. Linear regression fit parameters of QTc-HR (slope and
R
²) were utilized for performance assessment. To evaluate the accuracy of the predicted QTc, we acquired epicardial electrical and optical voltage data from Langendorff-perfused guinea pig hearts.

RESULTS:

In both human subjects and guinea pigs, the QTcAd formula (QTcAd=QT+(|
m
|×(HR−HR
mean
)) consistently outperformed other formulae across all age groups. For instance, in a 20-year-old human group, the QTcAd formula successfully nullified the inverse QT-HR relationship (
R
²=5.1×10
−10
, slope=−3.5×10
−5
), whereas the Bazett formula failed to achieve comparable effectiveness (
R
²=0.21, slope=0.91). Moreover, the QTcAd formula exhibited better accuracy than the age-specific Benatar QTc formula, which overcorrected QTc (1-week human QT: 263.8±14.8 ms, QTcAd: 263.8±7.3 ms,
P
=0.62; Benatar QTc: 422.5±7.3 ms,
P
<0.0001). The optically measured pseudo-QT interval (143±22.5 ms, n=44) was better approximated by QTcAd (180.6±17.0 ms) compared with all other formulae. Furthermore, we demonstrated that the QTcAd formula was not inferior to individual-specific QTc formulae.

CONCLUSIONS:

The demography-based QTcAd formula showed superior performance across human and guinea pig age groups, which may enhance the efficacy of rate-corrected K.M.M. for cardiovascular disease diagnosis, risk stratification, and drug safety testing in children and adults.